Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Disparities in HIV Viral Suppression Among Adolescents and Young Adults by Perinatal Infection.

Patel K, Seage GR 3rd, Burchett SK, Hazra R, Van Dyke RB; Pediatric HIV/AIDS Cohort Study.

Am J Public Health. 2019 Jul;109(7):e9. doi: 10.2105/AJPH.2019.305108. No abstract available.

PMID:
31166735
2.

Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol.

Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ; Pediatric HIV/AIDS Cohort Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 Protocol; Pediatric HIV/AIDS Cohort Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 Protocol.

Clin Infect Dis. 2017 Sep 15;65(6):982-989. doi: 10.1093/cid/cix488.

3.

Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.

Neilan AM, Karalius B, Patel K, Van Dyke RB, Abzug MJ, Agwu AL, Williams PL, Purswani M, Kacanek D, Oleske JM, Burchett SK, Wiznia A, Chernoff M, Seage GR 3rd, Ciaranello AL; Pediatric HIV/AIDS Cohort Study and the International Maternal Adolescent and Pediatric AIDS Clinical Trials Network.

JAMA Pediatr. 2017 May 1;171(5):450-460. doi: 10.1001/jamapediatrics.2017.0141.

4.

Lymphocyte subsets in HIV-exposed uninfected infants and HIV-unexposed uninfected infants.

Huo Y, Patel K, Scott GB, Van Dyke RB, Siberry GK, Burchett SK, Shearer WT.

J Allergy Clin Immunol. 2017 Aug;140(2):605-608.e3. doi: 10.1016/j.jaci.2017.01.033. Epub 2017 Mar 6. No abstract available.

5.

Case Report of a Child after Hematopoietic Cell Transplantation with Acute Aspergillus Tracheobronchitis as a Cause for Respiratory Failure.

Gauguet S, Madden K, Wu J, Duncan C, Lee GS, Miller T, Klingensmith WC 4th, Burchett SK, van der Velden M.

Case Rep Pediatr. 2016;2016:9676234. Epub 2016 Nov 9.

6.

Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy.

Agwu AL, Yao TJ, Eshleman SH, Patel K, Huang W, Burchett SK, Siberry GK, Van Dyke RB; Pediatric HIVAIDS Cohort Study.

Pediatr Infect Dis J. 2016 Jul;35(7):777-81. doi: 10.1097/INF.0000000000001158.

7.

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.

Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M; IMPAACT P1026s Protocol Team.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):289-96. doi: 10.1097/QAI.0000000000000968.

8.

Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R; Pediatric HIV/AIDS Cohort Study (PHACS), Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E.

Clin Infect Dis. 2016 Jan 1;62(1):106-114. doi: 10.1093/cid/civ734. Epub 2015 Sep 18.

9.

Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.

Siberry GK, Patel K, Bellini WJ, Karalius B, Purswani MU, Burchett SK, Meyer WA 3rd, Sowers SB, Ellis A, Van Dyke RB; Pediatric HIV AIDS Cohort Study (PHACS); Pediatric HIV AIDS Cohort Study PHACS.

Clin Infect Dis. 2015 Sep 15;61(6):988-95. doi: 10.1093/cid/civ440. Epub 2015 Jun 9.

10.

Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.

Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):33-41. doi: 10.1097/QAI.0000000000000668.

11.

Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.

Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team.

HIV Med. 2015 Mar;16(3):176-83. doi: 10.1111/hiv.12195. Epub 2014 Nov 18.

12.

Raltegravir pharmacokinetics during pregnancy.

Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M; IMPAACT 1026s study team.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):375-81. doi: 10.1097/QAI.0000000000000318.

13.

Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.

Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y.

Inflamm Bowel Dis. 2013 Jun;19(7):1441-9. doi: 10.1097/MIB.0b013e318281341b.

14.

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66. doi: 10.1097/QAI.0b013e318289b4d2.

15.

The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy.

Lo MS, Lee GM, Gunawardane N, Burchett SK, Lachenauer CS, Lehmann LE.

Pediatr Transplant. 2013 Mar;17(2):133-43. doi: 10.1111/petr.12022. Epub 2012 Dec 10.

PMID:
23228170
16.

T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children.

Kapetanovic S, Aaron L, Montepiedra G, Burchett SK, Kovacs A.

AIDS. 2012 May 15;26(8):959-69. doi: 10.1097/QAD.0b013e328352cee7.

17.

Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants.

Ehlinger EP, Webster EM, Kang HH, Cangialose A, Simmons AC, Barbas KH, Burchett SK, Gregory ML, Puopolo KM, Permar SR.

J Infect Dis. 2011 Dec 1;204(11):1672-82. doi: 10.1093/infdis/jir632. Epub 2011 Oct 7. Erratum in: J Infect Dis. 2012 Jun;205(11):1767. Puopolo, Karen P [corrected to Puopolo, Karen M].

18.

Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies.

Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA.

Clin Infect Dis. 2011 Apr 15;52(8):1003-9. doi: 10.1093/cid/cir121.

19.

CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption.

Siberry GK, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, Paul ME, Read JS, Wiznia A, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study(PHACS).

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):223-9. doi: 10.1097/QAI.0b013e318218e068.

20.

Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.

Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):165-73. doi: 10.1097/QAI.0b013e318215c7b1.

21.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

22.

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):381-8.

23.

Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants.

Brogly SB, Foca M, Deville JG, Mirochnick M, Scott GB, Mofenson LM, Read JS, Viani RM, Burchett SK, Cooper ER, Browning R, Shapiro DE.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):154-7. doi: 10.1097/QAI.0b013e3181b3adc2. No abstract available.

24.

Lopinavir protein binding in HIV-1-infected pregnant women.

Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team.

HIV Med. 2010 Apr;11(4):232-8. doi: 10.1111/j.1468-1293.2009.00767.x. Epub 2009 Dec 3.

25.

CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.

Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

J Acquir Immune Defic Syndr. 2010 Jul;54(3):285-9. doi: 10.1097/QAI.0b013e3181bf648a.

26.

Immune response to influenza vaccine in children with inflammatory bowel disease.

Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A.

Am J Gastroenterol. 2009 Feb;104(2):444-53. doi: 10.1038/ajg.2008.120. Epub 2009 Jan 27.

27.

Lopinavir exposure with an increased dose during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS; PACTG 1026s Study Team.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485-91. doi: 10.1097/QAI.0b013e318186edd0.

28.

Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M.

HIV Med. 2008 Nov;9(10):875-82. doi: 10.1111/j.1468-1293.2008.00640.x. Epub 2008 Sep 14.

29.

Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.

Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM Jr, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M; PACTG 1026S Study Team; PACTG P1022 Study Team.

HIV Med. 2008 Apr;9(4):214-20. doi: 10.1111/j.1468-1293.2008.00553.x.

30.

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

AIDS. 2007 Oct 18;21(16):2191-9.

PMID:
18090046
31.

Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort.

Handelsman E, Cheng I, Thompson B, Hershow R, Mofenson LM, Hollinger FB, Chen KT, Burchett SK, Klinzman D, Stapleton JT; Women and Infants Transmission Study Group (WITS).

HIV Med. 2007 Nov;8(8):561-7. Erratum in: HIV Med. 2008 Jan;9(1):64.

32.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
33.

Impact of pregnancy on abacavir pharmacokinetics.

Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD; PACTG P1026s Study Team.

AIDS. 2006 Feb 28;20(4):553-60.

PMID:
16470119
34.

Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.

Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK; Pediatric AIDS Clinical Trials Group 366 Study Team.

J Infect Dis. 2005 Jul 15;192(2):296-302. Epub 2005 Jun 14.

PMID:
15962224
35.

Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.

Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK.

J Infect Dis. 2004 Dec 15;190(12):2167-74. Epub 2004 Nov 10.

PMID:
15551216
36.

Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy.

Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK; Pediatric AIDS Clinical Trials Group 366 Team.

Clin Infect Dis. 2004 Jul 1;39(1):107-14. Epub 2004 Jun 14.

PMID:
15206061
37.

Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents.

Soh CH, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, Foca MD, Handelsman E, Jiménez E, Dankner WM, Hughes MD; Pediatric AIDS Clinical Trials Group.

Lancet. 2003 Dec 20;362(9401):2045-51.

PMID:
14697803
38.

Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.

Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.

J Immunol. 2003 Dec 15;171(12):6968-75.

39.

Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children.

Feeney ME, Roosevelt KA, Tang Y, Pfafferott KJ, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.

J Virol. 2003 Jul;77(13):7492-501.

40.

HIV infection in infants, children, and adolescents.

Burchett SK, Pizzo PA.

Pediatr Rev. 2003 Jun;24(6):186-94. Review. No abstract available.

PMID:
12777610
41.

Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation.

Goulder PJ, Pasquier C, Holmes EC, Liang B, Tang Y, Izopet J, Saune K, Rosenberg ES, Burchett SK, McIntosh K, Barnardo M, Bunce M, Walker BD, Brander C, Phillips RE.

Immunol Lett. 2001 Nov 1;79(1-2):109-16.

PMID:
11595297
42.

Evolution and transmission of stable CTL escape mutations in HIV infection.

Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD.

Nature. 2001 Jul 19;412(6844):334-8.

PMID:
11460164
43.

The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.

Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL.

Pediatrics. 2001 May;107(5):E77.

PMID:
11331727
44.

Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.

Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE Jr, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD.

J Exp Med. 2000 Dec 18;192(12):1819-32.

45.

Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group.

Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thompson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA.

J Infect Dis. 2000 Dec;182(6):1616-24. Epub 2000 Nov 8.

PMID:
11069232
46.

Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children.

Lindsey JC, Hughes MD, McKinney RE, Cowles MK, Englund JA, Baker CJ, Burchett SK, Kline MW, Kovacs A, Moye J.

J Infect Dis. 2000 Nov;182(5):1385-93. Epub 2000 Sep 22.

PMID:
11010839
47.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF.

N Engl J Med. 1999 Aug 5;341(6):394-402.

48.

Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis.

Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA.

J Neuroimmunol. 1998 Nov 2;91(1-2):19-27.

PMID:
9846815
49.

Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1.

Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, Brown ZA, Corey L.

Am J Obstet Gynecol. 1997 Aug;177(2):450-4.

PMID:
9290467
50.

Supplemental Content

Loading ...
Support Center